Abstract Objective: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus than the general population, and even first-episode, drug-naive (FEDN) patients with schizophrenia have shown a higher prevalence of impaired glucose tolerance (IGT) than the general population. We aimed to investigate the prevalence of abnormal glucose tolerance after glucose loading, and to examine the relationship between IGT and clinical phenotypes or cognitive deficits in FEND patients with schizophrenia among a Han Chinese population. Method: 175 inpatients meeting DSM-IV schizophrenia criteria were compared with 31 healthy controls on anthropometric measures and fasting plasma levels of glucose, insulin and lipids. They were also compared using a 75-g oral glucose tolerance test (OGTT) and a homeostasis model assessment of insulin resistance (HOMA-IR). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: Among the patients, 24.5% had IGT, compared to none of the healthy controls. Also, the patients had significantly higher levels of fasting glucose and two-hour glucose, and were more insulin resistant as measured with HOMA. Compared to those patients without IGT, the IGT patients were older, had a later age of schizophrenia onset, higher waist or hip circumference and BMI, higher levels of low-density lipoprotein and triglycerides and higher insulin resistance. Furthermore, IGT patients had higher PANSS total and negative symptom subscale scores, but no greater cognitive impairment except on the emotional intelligence index of the MCCB. Conclusions: More IGT occurs in FEDN patients with schizophrenia than controls, and is associated with demographic and anthropometric parameters, as well as with clinical symptoms but minimally with cognitive impairment, suggesting that abnormal glucose metabolism may be associated with clinical symptoms but not with cognitive impairment in schizophrenia during the early phases of the disease. The serotonergic hallucinogen psilocybin, has profound effects on the human mind, which can be characterized by alteration in perception, thinking disorder and strong emotional salience. The character of the altered state of consciousness induced by hallucinogens is hardly predictable; while an important role has the environment in which psilocybin is administered (setting). Methods: Twenty volunteers completed the psilocybin (0.26 mg/ kg, average dose 18.7 mg) session in a double-blind, placebo-controlled arrangement in a comfortable living-room-like setting. This study describes the phenomenology (evaluated objectively by Brief Psychiatric Rating Scale (BPRS) and subjectively by Altered States of Consciousness Scale (ASCS)), physiological parameters and pharmacokinetics of psilocybin intoxication. It also focuses on the relationship between electrophysiological measures of brain activity and phenomenology. Results: The effects of psilocybin peaked in 60 minutes (average blood levels 20 ng/ml) and subsided after 6 hours (average blood levels 4 ng/ml). Psilocybin induced mydriasis (rarely anisocoria), an increase in blood pressure and heart rate compared to placebo. A significant increase of psychopathology was documented by BPRS (subscale thought disorder and hallucinations) and ASCS (subscales visual restructuralization, oceanic boundlessness and to a lesser extent anxious ego dissolution). Psilocybin decreased the EEG spectral power in alpha frequency band, however increased the power of gamma oscillations. The LORETA analysis revealed the source of decreased alpha in midline parietal structures and occipital lobes. The increase in higher frequencies was pronounced in large temporal areas. EEG findings will be correlated with neuropsychiatric scales. Conclusion: We confirmed the safety and beneficial effects of psilocybin administration in a clinical trial under controlled experimental conditions. The decrement of EEG alpha activity was observed mainly in brain structures involved in Default Mode Network, which is thought to represent introspective processes. We hope that these findings will help facilitate future clinical trials using psychedelic substances in patients.
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